Drugs / Casdozokitug
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06679985 | Dec 2024 → Sep 2027 expected | hepatocellular carcinoma | Coherus Oncology, Inc. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05359861 | Apr 2022 → Jun 2025 | hepatocellular carcinoma | Coherus Oncology, Inc. | Terminated | No outcome recorded Stop: Business |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2025-01-22 | Coherus Oncology, Inc. | Results Coherus Presents Final Phase 2 Clinical Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025 coherus.com ↗
Importantly, responses were seen in viral and nonviral disease, and toxicity was consistent with the known safety profiles of atezolizumab and bevacizumab, with no new safety signals identified. |
| 2024-01-18 | Coherus Oncology, Inc. | Results Coherus Presents Positive Phase 2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2024 ASCO GI Cancers Symposium coherus.com ↗
Data demonstrate early activity with casdozokitug/atezolizumab/bevacizumab; 38% objective response rate including three complete responses |
| 2023-12-06 | Coherus Oncology, Inc. | Results Coherus Presents Phase 1/2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2023 ESMO Immuno-Oncology Congress coherus.com ↗
The overall response rate (ORR) in the subset of patients with squamous NSCLC (n=2/9) was 22% in this data cut. |
| 2023-11-03 | Coherus Oncology, Inc. | Results Coherus Presents Data from Next-generation Immuno-oncology Programs at 38th Annual Meeting of Society for Immunotherapy of Cancer (SITC) coherus.com ↗
Data demonstrate distinct IL-27-mediated expression of genes associated with immune suppression in vitro, supporting ongoing clinical development of first-in-class anti-IL-27 antibody casdozokitug |
All press releases naming this drug 5 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-01-22 | Coherus Oncology, Inc. | Coherus Presents Final Phase 2 Clinical Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025 coherus.com ↗ |
| 2024-12-18 | Coherus Oncology, Inc. | Coherus to Present Final Phase 2 Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025 coherus.com ↗ |
| 2024-01-18 | Coherus Oncology, Inc. | Coherus Presents Positive Phase 2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2024 ASCO GI Cancers Symposium coherus.com ↗ |
| 2023-12-06 | Coherus Oncology, Inc. | Coherus Presents Phase 1/2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2023 ESMO Immuno-Oncology Congress coherus.com ↗ |
| 2023-11-03 | Coherus Oncology, Inc. | Coherus Presents Data from Next-generation Immuno-oncology Programs at 38th Annual Meeting of Society for Immunotherapy of Cancer (SITC) coherus.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Casdozokitug | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06679985 ↗ |
| Known as | SRF-388 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314661 ↗ |
| Modality | Monoclonal antibody | — CHEMBL5314661 ↗ |
| Route | Intravenous | “Casdozokitug will be administered by intravenous injection (IV)” NCT05359861 ↗ |